NDAORALPOWDERPriority Review
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 34m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CALCIBIND (cellulose sodium phosphate) is an oral powder medication that binds dietary calcium in the gastrointestinal tract. It is used to treat hypercalciuria and related calcium-based kidney stone disease by reducing urinary calcium excretion. The drug works through ion-exchange mechanisms to sequester calcium and prevent its systemic absorption.
LOE Approaching
Product is in late-stage lifecycle with low competitive pressure (30%), indicating a mature franchise with defensive rather than growth-oriented commercial priorities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CALCIBIND represents a niche, mature franchise with zero linked job openings, indicating limited hiring and team expansion. Career growth on this product requires focus on operational efficiency, market defense, and creative retention strategies rather than launching new commercial infrastructure.
Brand ManagerField Sales Representative
Worked on CALCIBIND at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.